This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: Opportunities for Participation

SSC Subcommitte Shares Registry on the Use of DOACs for Treatment of Unusual Site VTE

Friday, May 29, 2020   (0 Comments)
Share |
The SSC Subcommittee on the Control of Anticoagulation invites participation in an international registry on the use of direct oral anticoagulants (DOACs) for treatment of unusual site venous thromboembolism (VTE). This is an international observational study of patients with thrombosis in unusual venous sites treated with DOACs. The aim of this project is to assess the rationale and the safety and effectiveness of this approach. 

This is a multicenter, international, observational study of patients with objective diagnosis of thrombosis in unusual sites (i.e. with the exclusion of thrombosis of the upper limbs, lower limbs and pulmonary arteries) treated with one of the DOACs. The registry will collect information on timing of initiation of the DOAC, reasons for starting/switching to the DOAC, occurrence of thrombotic events, major bleeding, and mortality during follow up. A minimum follow up of six months (maximum 12 months) is requested for each patient. If you are interested in participating, please contact Dr. Nicoletta Riva at

Membership Management Software Powered by YourMembership  ::  Legal